{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:34:22Z","timestamp":1787319262563,"version":"build-2736575974"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100014054","name":"Drugs for Neglected Diseases initiative","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["206379\/Z\/17\/Z"],"award-info":[{"award-number":["206379\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,4,21]]},"abstract":"<jats:p>In children requiring lopinavir coformulated with ritonavir in a 4:1 ratio (lopinavir-ritonavir-4:1) and rifampin, adding ritonavir to achieve a 4:4 ratio with lopinavir (LPV\/r-4:4) overcomes the drug-drug interaction. Possible drug-drug interactions within this regimen may affect abacavir concentrations, but this has never been studied. Children weighing &lt;15\u2009kg needing rifampin and LPV\/r-4:4 were enrolled in a pharmacokinetic study and underwent intensive pharmacokinetic sampling on 3 visits: (i) during the intensive and (ii) continuation phases of antituberculosis treatment with LPV\/r-4:4 and (iii) 1 month after antituberculosis treatment completion on LPV\/r-4:1.<\/jats:p>","DOI":"10.1128\/aac.01923-19","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T08:10:19Z","timestamp":1581927019000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir"],"prefix":"10.1128","volume":"64","author":[{"given":"Helena","family":"Rabie","sequence":"first","affiliation":[{"name":"Family Centre for Research with Ubuntu, Stellenbosch University, Cape Town, South Africa"},{"name":"Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjokosela","family":"Tikiso","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Lee","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Fairlie","sequence":"additional","affiliation":[{"name":"Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Strehlau","sequence":"additional","affiliation":[{"name":"Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raziya","family":"Bobat","sequence":"additional","affiliation":[{"name":"Enhancing Care Foundation\u2014Durban International Clinical Research, Wentworth Hospital, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaaf","family":"Liberty","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Andrieux-Meyer","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cotton","sequence":"additional","affiliation":[{"name":"Family Centre for Research with Ubuntu, Stellenbosch University, Cape Town, South Africa"},{"name":"Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lallemant","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-079X","authenticated-orcid":false,"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/135965350501000207","article-title":"Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13)","volume":"10","author":"Bergshoeff A","year":"2005","unstructured":"Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, Le Prevost M, Walker S, Novelli V, Lyall H, Khoo S, Gibb D, PENTA-13 Study Group. 2005. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 10:239\u2013246.","journal-title":"Antivir Ther"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1532"},{"key":"e_1_3_2_5_2","volume-title":"The Western Cape consolidated guidelines for HIV treatment: prevention of mother- to- child transmission of HIV (PMTCT), children, adolescents and adults (amended version)","author":"Western Cape Health Department","year":"2018","unstructured":"Western Cape Health Department. 2018. The Western Cape consolidated guidelines for HIV treatment: prevention of mother- to- child transmission of HIV (PMTCT), children, adolescents and adults (amended version). Western Cape Health Department, Cape Town, South Africa."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182076864"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.44.6.1686-1690.2000"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847060-00001"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12024"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000337"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113249"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/b:pham.0000041457.64638.8d"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.1133"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1682"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.2174\/187231210790980453"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2010.516251"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.033126"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/135965350701200510","article-title":"Abacavir plasma pharmacokinetics in the absence and presence of atazanavir\/ritonavir or lopinavir\/ritonavir and vice versa in HIV-infected patients","volume":"12","author":"Waters LJ","year":"2007","unstructured":"Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M. 2007. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir\/ritonavir or lopinavir\/ritonavir and vice versa in HIV-infected patients. Antivir Ther 12:825\u2013830.","journal-title":"Antivir Ther"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw139"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038010-00003"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2007.00811.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182456ba2"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30293-5"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1910"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00319-9"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.609"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.234"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02337.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.103.4.e47"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.11.932.31568"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90065-0"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.898"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12934"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02456.x"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03964.x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01000-08"},{"key":"e_1_3_2_37_2","first-page":"48","volume-title":"NONMEM user\u2019s guide\u2014part V. Introductory guide","author":"Boeckmann AJ","year":"1998","unstructured":"Boeckmann AJ, Beal SL, Sheiner LB. 1998. NONMEM user\u2019s guide\u2014part V. Introductory guide p 48. NONMEM Project Group, University of California at San Francisco, San Francisco, CA."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_2_41_2","volume-title":"WHO child growth standards: head circumference-for-age, arm circumference-for-age, triceps skinfold-for-age and subscapular skinfold-for-age: methods and development","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. 2007. WHO child growth standards: head circumference-for-age, arm circumference-for-age, triceps skinfold-for-age and subscapular skinfold-for-age: methods and development. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-016-9487-8"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0577-6"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.44.8.2052-2060.2000"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01923-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01923-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T15:37:10Z","timestamp":1665848230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01923-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,21]]}},"alternative-id":["10.1128\/AAC.01923-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01923-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01923-19"}}